MedTrace Logo

To Assess the Effect of HDF Versus High Flux Dialysis on Free Light Chains and Cumulative Albumin Loss, in End Stage Renal Disease Patients.

NCT04747067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-03-16

No results posted yet for this study

Summary

Removal of uremic toxins is the main goal of HD, It was improved by using high volume convective technique with high flux (HF) dialyzer. This technique removes medium - large molecular weight solutes giving higher dialysis adequacy and consequently improving the quality of life.

This study will assess the effect of hemodiafiltration (HDF) versus high flux dialysis on free light chains (FLC) reduction as a marker of HD adequacy and its relation to albumin loss using dialyzer effective surface area 2.6m2.

Conditions

Interventions

DEVICE

BIOPURE 260HF dialyzer

Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Reem Sultan, M.Sc · Faculty of Medicine, Ain Shams Univeristy.

  • Hesham ElSayed, PhD · Faculty of Medicine, Ain Shams Univeristy

  • Magdy ElSharkawy, PhD · Faculty of Medicine, Ain Shams Univeristy

  • Waleed AbdelMohsen, PhD · Faculty of Medicine, Ain Shams Univeristy

  • Shaimaa Zaki, PhD · Faculty of Medicine, Ain Shams Univeristy

  • Ahmed Emara, PhD · Faculty of Medicine, Ain Shams Univeristy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-05-01
Completion
2021-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04747067 on ClinicalTrials.gov